For the first time in the firm's history, Takeda Chemical Industries'recurring profits have broken through the 100 billion yen ($863.9 million) level to 104 billion yen in the fiscal year ended March 31, an increase on the previous fiscal year of 13%. Net profits were just over 50 billion yen, up 20.9%.
The firm achieved sales of 637.2 billion yen during the year, a rise of 6%. Growth was driven by improved sales of prescription drugs including the treatment for diabetes, Basen (voglibose), and the prostate cancer agent Leuplin (leuprorelin acetate). Prescription drug sales grew 8%, and exports increased, influenced by the weakening of the yen.
On a consolidated basis, sales were 5% higher and net profit grew 19% to 71.4 billion yen. In the current year, Takeda expects a 1% increase in recurring profits to 104.5 billion yen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze